Image For Activity Cover
How to Screen for Monoclonal Gammopathy in Patients With a Suspected Amyloidosis (JACC: CardioOncology October 2021-3)
How to Screen for Monoclonal Gammopathy in Patients With a Suspected Amyloidosis

Amyloidosis is a category of rare diseases that result from deposition of abnormally folded proteins into organs. Light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR) are the most common forms in the United States. The diagnosis of AL amyloidosis involves establishing the presence of monoclonal protein. Cardiologists evaluating patients with concern for cardiac amyloidosis should be familiar with the concepts behind testing for monoclonal proteins. We use a case to illustrate our approach to screening for monoclonal gammopathies in patients with suspected amyloidosis and how identification of a monoclonal gammopathy changes our diagnostic approach for such patients.

JACC CardioOncology Editor-in-Chief and CME Editor
Bonnie Ky, MD, MSCE, FACC

Authors
Samuel M. Rubinstein, MD
Keith Stockerl-Goldstein, MD 

Important Dates

Date of Release: October 19, 2021    
Term of Approval/Date of CME/MOC/ECME Expiration: October 18, 2022 

Summary
Availability: On-Demand
Expires on Oct 18, 2022
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 ECME Credit
Android App Download IOS App Download Powered By